Uncategorized
Intravitreal implant with brimonidine reduced GA lesion growth in phase 2 study
BALTIMORE — A brimonidine drug delivery system was well tolerated and reduced geographic atrophy lesion growth, nearing statistical significance at year 2 with a higher dose, based on a phase 2, multicenter, double-masked study presented at the Association for Research in Vision and Ophthalmology annual meeting.“In the AMD arena where there is a dire need and no treatments for geographic atrophy available, this is showing some signs of promise in a drug that we’ve had our hands on for over a decade,” Baruch D. Kuppermann, MD, PhD, said in an (Read more...)